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Background. Survivors of infant group B streptococcal (GBS) disease are at risk of neurodevelopmental impairment (NDI), a 
burden not previously systematically quantified. This is the 10th of 11 articles estimating the burden of GBS disease. Here we aimed 
to estimate NDI in survivors of infant GBS disease.
Methods. We conducted systematic literature reviews (PubMed/Medline, Embase, Latin American and Caribbean Health 
Sciences Literature [LILACS], World Health Organization Library Information System [WHOLIS], and Scopus) and sought unpub-
lished data on the risk of NDI after invasive GBS disease in infants <90 days of age. We did meta-analyses to derive pooled estimates 
of the percentage of infants with NDI following GBS meningitis.
Results. We identified 6127 studies, of which 18 met eligibility criteria, all from middle- or high-income contexts. All 18 studies 
followed up survivors of GBS meningitis; only 5 of these studies also followed up survivors of GBS sepsis and were too few to pool 
in a meta-analysis. Of meningitis survivors, 32% (95% CI, 25%–38%) had NDI at 18 months of follow-up, including 18% (95% CI, 
13%–22%) with moderate to severe NDI.
Conclusions. GBS meningitis is an important risk factor for moderate to severe NDI, affecting around 1 in 5 survivors. However, 
data are limited, and we were unable to estimate NDI after GBS sepsis. Comparability of studies is difficult due to methodological 
differences including variability in timing of clinical reviews and assessment tools. Follow-up of clinical cases and standardization 
of methods are essential to fully quantify the total burden of NDI associated with GBS disease, and inform program priorities.
Keywords. Group B Streptococcus; impairment; infants; disability; estimate.
 
During the Millennium Development Goal era, there have been 
considerable achievements in child survival worldwide, although 
progress for neonatal deaths (days 0–27) has been slower [1, 2]. In 
the era of the Sustainable Development Goals, there is continued 
emphasis on survival, to end preventable newborn and child 
deaths, but also to move beyond survival to improved health 
and maximized child well-being [3]. This shift is highlighted 
in the World Health Organization (WHO) Global Strategy for 
Women’s, Children’s, and Adolescents’ Health, and the 3 pillars of 
survive, thrive, and transform [4]. As maternal and newborn care 
improves in low- and middle-income countries, there may be an 
increase in neurodevelopmental impairment (NDI), including in 
survivors of invasive infection, as was observed in high-income 
countries following advances in perinatal care [5, 6].
Infection is an important cause of neonatal and infant 
death [1]. What is less well recognized is the burden of NDI 
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in survivors of infant infection. NDI may follow invasive infec-
tions including pneumonia, sepsis, and meningitis [7]. The 
neuroimaging findings, mechanisms of brain injury, and subse-
quent NDI after invasive infectious disease are outlined in Box 
1. Data are insufficient to estimate the risk after invasive neona-
tal disease other than meningitis, after which around 23% (95% 
confidence interval [CI], 19%–26%) of survivors are estimated 
to have moderate to severe NDI [7]. Intrauterine and neonatal 
insults, including infections, are estimated to cause NDI in 39% 
(interquartile range [IQR], 20%–55%) of survivors [8].
Group B Streptococcus (GBS; Streptococcus agalactiae) is a 
leading cause of infant sepsis and meningitis. Its contribution to 
NDI and associated disability has not, however, previously been 
assessed by a comprehensive systematic review or pooled esti-
mates. The long-term consequences of infant GBS disease are 
important to understand, to estimate the full burden of GBS dis-
ease, including in terms of standard measures used to assess public 
health priorities, such as disability-adjusted life-years (DALYs).
We aimed to estimate the percentage of survivors 
of infant GBS disease with NDI (Figure 1) as part of a 
supplement estimating the burden of GBS disease in preg-
nant women, stillbirths, and infants, which is important in 
terms of public health policy, particularly vaccine develop-
ment, as outlined elsewhere in this supplement [17]. The 
supplement includes systematic reviews and meta-analyses 
on GBS colonization and adverse outcomes associated with 
GBS around birth [16,18–24]. These are reported individ-
ually according to international guidelines [25, 26] and are 
used for estimates of the burden of GBS worldwide [27] 
(Figure 1).
OBJECTIVES
1. To provide a comprehensive, systematic literature review and 
meta-analyses to assess the following parameters: (i) percentage 
of survivors with any NDI after infant GBS disease; (ii) percentage 
of survivors with moderate to severe NDI after infant GBS disease.
2. To assess these data for input to estimate the burden of GBS 
in pregnancy, stillbirth, and infants.
3. To evaluate the data gaps and make recommendations to 
improve the data on NDI after infant GBS disease.
METHODS
This article is part of a study entitled “Systematic estimates of 
the global burden of GBS worldwide in pregnant women, still-
births and infants.” It was submitted for ethical approval to the 
London School of Hygiene & Tropical Medicine (reference 
number 11966) and approved on 30 November 2016.
Exposure
Case definitions for invasive infant GBS disease include GBS 
meningitis (clinical signs of possible serious bacterial infec-
tion and cerebrospinal fluid (CSF) culture /polymerase chain 
reaction (PCR)/latex agglutination positive for GBS or blood 
culture/PCR/latex agglutination positive for GBS with CSF leu-
kocyte count of >20 × 106/L), GBS sepsis (clinical signs of pos-
sible serious bacterial infection and blood culture/PCR/latex 
agglutination positive for GBS), and GBS pneumonia. These 
definitions are fully described in Supplementary Table 1a.
Outcome
The outcome of interest is NDI. Impairment is defined as a prob-
lem in body function and structure such as significant deviation 
or loss (Supplementary Table 2) [28]. For this analysis of NDI, we 
combined the specific definitions used by the Global Burden of 
Disease study 2013 (GBD2013) [29] and others [30] to be consist-
ent with the literature. Therefore, NDIs are categorized as intel-
lectual and/or motor, vision, or hearing impairment and severity 
classified as mild, moderate, or severe. To maintain consistency 
with GBD2013 definitions, we did not include social, language, 
and behavioral NDI in the quantitative analysis for this review. 
Disability weights for each impairment domain and severity used 
in GBD2013 are also listed in Supplementary Table 1b.
Box 1. Neuroimaging, Mechanisms of Brain Injury, and 
Neurodevelop mental Impairment After Infant Meningitis 
and Sepsis
Meningitis and sepsis can cause brain injury in term and 
preterm infants. Magnetic resonance imaging (MRI) find-
ings consistently show cerebrovascular involvement, and 
abnormal findings on neonatal MRI have been clearly asso-
ciated with poor neurodevelopmental outcome at 2  years 
[9]. A retrospective cohort study in France found that all 9 
cases of infant GBS meningitis in term babies had abnormal 
findings on MRI, of which 56% showed ischemic infarc-
tion (neonatal stroke). Furthermore, a case series of 8 term 
infants with GBS meningitis and ischemic stroke on MRI 
found 2 recognizable patterns of injury, deep perforator 
arterial infarction, and more superficial cortical injury [10, 
11]. Case reports of neuroimaging in term infants with GBS 
meningitis have also found severe global cerebral vasculop-
athy and transverse myelitis [12, 13]. In preterm infants, 
inflammatory cytokines associated with infection increase 
the permeability of the blood–brain barrier and have an 
adverse effect on myelin and myelin-producing cells, result-
ing in periventricular leukomalacia, a condition strongly 
associated with neurodisability [14, 15]. In addition, sepsis 
causes brain injury indirectly through disseminated intra-
vascular coagulopathy and hypotension; this is important to 
consider in cases of neonatal sepsis without meningitis [15]. 
Furthermore, bloodstream infection can have a sensitizing 
effect in the development of hypoxic-ischemic encepha-
lopathy, which is also associated with neurodevelopmental 
impairment [16].
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Data Searches and Inputs
We identified data through systematic review of the published 
literature and through development of an investigator group 
surveying clinicians, researchers, and relevant professional 
institutions worldwide. For this paper, we did systematic lit-
erature searches of PubMed/Medline, Embase, the World 
Health Organization Library Information System (WHOLIS), 
Literature in the Health Sciences in Latin America and the 
Caribbean (LILACS), and Scopus until January 2017. We 
searched databases with variants of terms related to “child,” 
“disability,” “impairment,” “GBS,” “morbidity,” and “mortal-
ity.” Medical subject heading (MeSH) terms were used where 
possible (see Supplementary Table 3 for the full list of search 
terms). There were no date and/or language restrictions 
applied and we translated texts to English when published in 
other languages. We used snowball searches of article refer-
ence lists to identify additional studies. We requested unpub-
lished data from an international network of investigators. 
Where reporting of child neurodevelopmental outcomes was 
not clear, or outcomes were not reported separately for GBS, 
we contacted authors for clarification of terms and defini-
tions used, and assessment of survivors of infant GBS disease. 
If authors were uncontactable, 2 clinicians (M. K.  L., N.  R.) 
discussed and came to a consensus to classify impairment. 
We matched NDI outcomes to GBD2013 and International 
Classification of Diseases [31] definitions to ensure optimal 
comparability between studies.
The full search strategy is illustrated in Figure  2 [26]. Two 
independent investigators (M. K. L., N. R.) performed the data-
base searches, screened titles for duplicates and for eligibility, and 
screened abstracts to assess their suitability for inclusion, and both 
reviewers extracted data. Where there was discrepancy between 
the 2 reviewers, a third investigator (A. S.) made the final decision.
Inclusion and Exclusion Criteria
We included studies of infants with GBS disease in the first 90 
days after birth (see case definitions), which reported study char-
acteristics and assessed child neurodevelopmental outcomes at 
a median of ≥6 months of age. Studies with nonrepresentative 
samples of cases (eg, with a selection bias of preterm births) and 
unsuitable article types were excluded (Supplementary Table 
4). Only cases of moderate or severe NDI were included in the 
main meta-analysis as there was lack of consistency in defini-
tion and proportions of survivors with mild or profound NDI.
The quality of the studies and risks of bias were assessed using 
inclusion and exclusion criteria (see Supplementary Table 4) on 
Figure 1. Neurodevelopmental impairment after infant group B streptococcal (GBS) disease in the disease schema for GBS, as described by Lawn et al [17]. Abbreviations: 
GBS, group B Streptococcus; NE, neonatal encephalopathy.
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validity of study methods, interpretation of results, and applica-
bility of the results.
Data Collection
Data on study characteristics and results were extracted into 
prespecified Excel abstraction forms, and then imported to Stata 
14 software (StataCorp, La Jolla, California) for meta-analyses.
Meta-analyses were done to assess risk of NDI by severity, 
length of follow-up, and neonatal mortality rate (NMR) (per 
1000 live births) context.
We used random-effects meta-analyses to estimate risk of NDI 
using the DerSimonian and Laird method [32]. The primary 
meta-analysis was of GBS meningitis survivors followed up for a 
median of ≥18 months with moderate to severe NDI. We decided 
to focus on moderate to severe impairment as more consistent 
results are seen with moderate to severe NDI [33] and there was lack 
of consistency in the definition and proportions of survivors with 
mild NDI. We chose a median follow-up of ≥18 months to include 
as many studies as possible while demonstrating the most accurate 
possible estimate of NDI, and cases of NDI are likely to manifest with 
longer-term follow-up. A threshold NMR of 5 per 1000 live births 
was used for the sensitivity analyses to reflect newborn care context 
as high-income countries have an average NMR of 4 per 1000 [34]. 
Given lack of variation with varying NMR settings (see below), we 
did not report the primary meta-analysis by NMR setting.
The following sensitivity meta-analyses were done to assess the 
effect of length of follow-up, severity of NDI, and NMR setting: 
(1) GBS meningitis survivors followed up for a median of ≥18 
months with any NDI; (2) GBS meningitis survivors followed up 
for a median of ≥18 months with moderate to severe NDI where 
NMR was ≥5 per 1000 live births; (3) GBS meningitis survivors 
followed up for a median of ≥18 months with moderate to severe 
NDI where NMR was <5 per 1000; (4) GBS meningitis survivors 
followed up for a median of ≥6 months with any NDI; (5) GBS 
meningitis survivors followed up for a median of ≥6 months 
with moderate to severe NDI; (6) GBS meningitis survivors fol-
lowed up for a median of ≥6 months with moderate to severe 
NDI where NMR was ≥5 per 1000; (7) GBS meningitis survivors 
Figure 2. Data search and selection. Abbreviation: GBS, group B Streptococcus.
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followed up for a median of ≥6 months with moderate to severe 
NDI where NMR was <5 per 1000.
RESULTS
Literature Search
We identified 6127 studies through database searches. Of these, 
118 full texts were reviewed and 16 studies met the inclusion 
criteria (Figure  2) [35–49]. Two unpublished datasets (Heath 
et al and Dangor et al) were provided by the investigator group, 
1 of which contained longer-term NDI outcomes of a cohort 
described in a published article. Overall, 18 studies were 
included in the quantitative analysis.
Study Characteristics
All 18 studies followed up survivors of infant GBS meningitis; 5 
of these studies also followed up survivors of infant GBS sepsis 
(Table 1). The numbers of GBS sepsis cases and survivors assessed 
were too few to pool in a meta-analysis (see Supplementary 
Table 5 for summary of results); therefore, we have meta-analyzed 
NDI outcomes after infant GBS meningitis only.
Ten of the 18 articles included were published between 1973 
and 1992. The remaining 8 studies were from 2000 onward. One 
article [38] contained datasets from 2 periods (1976 and 1983) and 
were entered into the meta-analyses separately. Years of data col-
lection ranged from 1970 to 2017, with the median years of data 
collection ranging from 1971 to 2016. Most (8/18) studies were 
done in the United States, 2 in the United Kingdom, 2 in Sweden, 
and 1 each in Germany, Denmark, Singapore, China, Tunisia, and 
South Africa, the latter 3 being the only studies conducted in mid-
dle-income contexts (Figure 3). The majority (15/18) of studies 
were carried out in hospitals, while 3 of 18 studies used national 
surveillance data. The median length of follow-up of infant 
GBS meningitis survivors ranged from 6  months to 10.5  years. 
Neonatal mortality rates at studies’ median point of data collection 
ranged from 1–15 per 1000 live births [51–54]. Further detailed 
characteristics of studies included after systematic review for NDI 
following infant GBS meningitis are given in Table 2.
A wide range of neurodevelopment assessment methods were 
applied. In total, 44 different methods were used (Supplementary 
Table 6); 31 methods were used to assess child cognitive, motor, lan-
guage, and socioemotional or behavioral development; 8 methods 
Table 1. Characteristics of Included Studies Investigating Neurodevelopmental Outcomes After Infant Group B Streptococcal Meningitis
UN Region UN Subregion Country Author
Publication 
Year
Followed 
Sepsis 
Cases (Yes/
No)
Median Year of 
Data Collection
NMR (per 
1000 Live 
Births) Facility
Minimum 
Median 
Follow-up, y
No. of ND 
Assess- 
ments
No. of GBS 
Meningitis 
Survivors (% of 
GBS Meningitis 
Cases)
Africa Southern Africa South AfricaDangor 
(unpublished)
…a Y 2014 11 Hospital 1 3 30 (85.7%)
Northern Africa Tunisia Ben Hamouda 
[36]
2013 N 2003 15 Hospital 5 1 7 (70.0%)
Americas Northern 
America
US Libster [45] 2012 N 2002 5 Hospital 6.8 1 85 (94.4%)
US Franco [42] 1992 N 1975 12 Hospital 4.5 19 10 (90.9%)
US Wald [47] 1986 N 1973 13 Hospital 10.5 1 54 (73.0%)
US Chin [40] 1985 N 1978 9 Hospital 4.3 5 21 (77.8%)
US Edwards [41] 1985 N 1976 10 Hospital 6 1 48 (78.7%)
US Haslam [43] 1977 N 1971 14 Hospital 3.6 1 15 (83.3%)
US Horn [44] 1974 Y Unknown 12 Hospital 1.6 1 7 (41.2%)
US Baker [35] 1973 N 1971 14 Hospital 0.5 1 23 (69.7%)
Asia Southeastern 
Asia
Singapore Wee [48] 2016 N 2005 1 Hospital 2 4 20 (95.2%)
Eastern Asia China Zhu [49] 2014 N 2009 9 Hospital 1.9 1 11 (84.6%)
Europe Northern 
Europe
UK Heath 
(unpublished)
… Y 2015 2 Hospital 3 1 37 (unknown 
as study 
ongoing)
UK Bedford [37] 2001 N 1986 5 National 
surveillance
5 1 103 (unknown)
Sweden Bennhagen [38] 1987 N (a) 1979; 
(b) 1983
(a) 6; 
(b) 4
National 
surveillance
(a) 1.5
(b) 1.5
(a) 1; (b) 1 (a) 16 (80.0%);
(b) 9 (100.0%)
Denmark Carstensen [39] 1985 Y 1980 6 National 
surveillance
0.75 Not reported 26 (74.3%)
Western 
Europe
Germany Schroder [46] 1982 Y 1975 9 Hospital 2.3 1 10 (unknown)
Total 532
Abbreviations: GBS, group B Streptococcus; ND, neurodevelopmental; NMR, neonatal mortality rate per 1000 live births; UK, United Kingdom; UN, United Nations; US, United States.
aThree- and 6-month neurodevelopmental follow-up assessment results have been published [50].
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to assess vision; and 9 methods to assess hearing. Not all studies 
covered all domains or described the methods (Supplementary 
Table 6). The number of child development assessments done for 
each child ranged from 1 to 19 (Supplementary Table 6).
The primary meta-analysis was for risk of moderate to 
severe NDI in survivors of infant GBS meningitis at a median 
≥18 months of follow-up.
When followed up over a median of 18 months, 18% (95% 
CI, 13%–22%) (Figure  4) of GBS meningitis survivors had 
moderate to severe NDI. There were insufficient data for esti-
mates by United Nations subregions, other than for devel-
oped countries, for which the estimate was also 18% (95% CI, 
13%–23%), reflecting the fact that this was where most data 
were from.
Figure  4. Infant group B Streptococcus meningitis survivors followed up for a median of ≥18  months with moderate to severe neurodevelopmental impairment. 
Abbreviations: CI, confidence interval; ES, effect size; GBS, group B Streptococcus; NDI, neurodevelopmental impairment.
Figure 3. Geographic spread of inputs for neurodevelopmental impairment after infant Group B Streptococcus meningitis. Borders of countries/territories in map do not 
imply any political statement.
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Sensitivity meta-analyses were for risk of NDI in survivors 
of infant GBS meningitis by severity, length of follow-up, and 
NMR (per 1000 live births) context.
A series of 7 meta-analyses (meta-analyses 1–7) acted as sen-
sitivity analyses to assess the variation of risk of NDI with as long 
follow-up as possible in different NMR settings. Supplementary 
Figure 1 demonstrates the number of studies included in each 
meta-analysis. 
1. GBS meningitis survivors followed up for median of 
≥18  months with any NDI: 32% (95% CI, 25%–38%) 
(Supplementary Figure 2) of infant GBS meningitis survivors 
had any NDI (mild, moderate, or severe) when followed up 
for a median of at least 18 months.
2. GBS meningitis survivors followed up for median of 
≥18 months with moderate to severe NDI where NMR ≥5 per 
1000: Percentage of GBS meningitis survivors with moderate 
to severe NDI was 18% (95% CI, 12%–24%) (Supplementary 
Figure 3) when followed up for a median of at least 18 months 
where NMR is ≥5 per 1000 live births.
3. GBS meningitis survivors followed up for median of 
≥18 months with moderate to severe NDI where NMR <5 per 
1000: At 18% (95% CI, 8%–28%) (Supplementary Figure 4), 
the percentage of GBS meningitis survivors with moderate to 
severe impairment where NMR is <5 per 1000 was very simi-
lar to results in settings where NMR is ≥5 per 1000 live births.
4. GBS meningitis survivors followed up for median of ≥6 months 
with any NDI: When followed up for a median of at least 
6 months, 27% (95% CI, 20%–34%) GBS meningitis survivors 
were reported to have any NDI (Supplementary Figure 5).
5. GBS meningitis survivors followed up for median of 
≥6  months with moderate to severe NDI: 15% (95% CI, 
11%–20%) of GBS meningitis survivors were reported to 
have moderate to severe NDI at a median of at least 6 months 
of follow-up (Supplementary Figure 6).
6. GBS meningitis survivors followed up for median of 
≥6  months with moderate to severe NDI where NMR is 
≥5 per 1000: The percentage of GBS meningitis survivors 
with moderate to severe NDI was 15% (95% CI, 10%–20%) 
(Supplementary Figure 7) when followed up for a median of 
at least 6 months where NMR is ≥5 per 1000 live births.
7. GBS meningitis survivors followed up for median of 
≥6 months with moderate to severe NDI where NMR is <5 
per 1000: A  slightly greater percentage of GBS meningitis 
survivors followed up for a median of at least 6 months in 
settings where NMR is <5 per 1000 had moderate to severe 
NDI, 18% (95% CI, 8%–28%) (Supplementary Figure  8), 
compared to settings where NMR is ≥5 per 1000.
Table 2 summarizes the results of the above meta-analyses, with 
more details in Supplementary Figures 2–8.
DISCUSSION
GBS is an important contributor to NDI after infant meningi-
tis, of which it is a leading cause. However, data are insufficient 
to assess its contribution to NDI after all infant GBS disease, 
which is important as there are many more cases of infant GBS 
sepsis compared to infant meningitis [27].
Our estimates of moderate to severe NDI following GBS 
meningitis in 18% (95% CI, 13%–22%) of survivors is consist-
ent with the estimate of NDI after meningitis of all infectious 
etiologies, which is 23% (95% CI, 19%–26%) [7]. The slightly 
lower point estimate may be due to differences in the geogra-
phies covered. In our analysis, there were no data from low-in-
come contexts, and data from only 3 middle-income contexts 
(China, Tunisia, and South Africa) and a higher proportion 
of data from developed countries compared to the previous 
work, which limits the generalizability of the NMR sensitivity 
analyses.
Table 2. Results of Meta-analyses for Sensitivity Testing to Assess Variation With Length of Follow-up and/or Severity of Neurodevelopmental Outcome 
by Neonatal Mortality Rate Setting
Meta-analysis Population Included
No. of Studies (No. of 
Children Followed up)
Percentage of GBS Meningitis Survivors With 
Neurodevelopmental Impairment (95% CI)
1. GBS meningitis survivors followed up for median of ≥18 mo 
with any NDI
15 (453) 32 (25–38)
2. GBS meningitis survivors followed up for median of ≥18 mo 
with moderate to severe NDI where NMR ≥5/1000
12 (387) 18 (12–24)
3. GBS meningitis survivors followed up for median of ≥18 mo 
with moderate to severe NDI where NMR <5/1000
3 (66) 18 (8–28)
4. GBS meningitis survivors followed up for median of ≥6 mo 
with any NDI
18 (532) 27 (20–34)
5. GBS meningitis survivors followed up for median of ≥6 mo 
with moderate to severe NDI
18 (532) 15 (11–20)
6. GBS meningitis survivors followed up for median of ≥6 mo 
with moderate to severe NDI where NMR ≥5/1000
15 (466) 15 (10–20)
7. GBS meningitis survivors followed up for median of ≥6 mo 
with moderate to severe NDI where NMR <5/1000
3 (66) 18 (8–28)
Abbreviations: CI, confidence interval; GBS, group B Streptococcus; NDI, neurodevelopmental impairment; NMR, neonatal mortality rate per 1000 live births.
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Improving the data are critical to direct public health inter-
ventions. Currently, and mainly in high-income contexts, ear-
ly-onset cases (the first week after birth) of invasive GBS disease 
are reduced through intrapartum antibiotic chemoprophylaxis, 
but maternal vaccination may offer an alternative strategy in the 
future, with the potential to reduce the morbidity, as well as the 
mortality burden from GBS disease, and be more feasible in set-
tings where a large proportion of deliveries occur at home. There 
were insufficient data to determine whether NDI in GBS men-
ingitis survivors varies between different mortality contexts. For 
settings with an NMR <5 per 1000 live births and ≥5 per 1000 live 
births, the risk of moderate to severe NDI was 18% (8%–28%) 
and 18% (12%–24%), respectively, at median follow-up of at least 
18 months. Whether there is a difference in very high-mortality 
settings (NMR  >15/1000 live births) is unknown. However, as 
>90% of the world’s births are in low- or middle-income contexts, 
the number of cases are likely to be highest in these contexts [2].
Overall it is likely that we are underestimating NDI after inva-
sive infant GBS disease, due to challenges in detection, particu-
larly at the youngest ages. As expected, the prevalence of NDI 
increased with follow-up to 18 months compared to 6 months 
(18% [95% CI, 13%–22%] vs 15% [95% CI, 11%–20%]). While 
we acknowledge that these confidence intervals overlap consid-
erably, the upward trend suggests that longer follow-up is needed 
for accurate case ascertainment. The range of assessment tools 
used for NDI diagnosis limits comparability, and demonstrates 
the need for standardization of methodologies, as well as valida-
tion of tools in different contexts. There were 44 different methods 
used in the studies in this review, which results in heterogeneity 
and lack of true comparability. This review is further limited by 
use of developmental screening tests by some studies, rather than 
diagnostic developmental assessments. While there is no uni-
versal gold standard for high-risk newborn follow-up, studies 
should ensure comprehensive neurodevelopment assessment of 
all domains, and of vision and hearing, and should align methods 
of assessment with contemporary studies. Neurodevelopment 
assessment tools, where not developed locally, should be trans-
lated, culturally adapted, and validated in the setting. NDI in 
GBS-associated preterm and neonatal encephalopathy survivors 
is also important to consider in estimating the total burden of 
GBS disease but was not investigated in this review.
To improve the data, ideally, we should systematically inves-
tigate infants with signs of possible serious bacterial infection to 
ascertain a bacterial infectious etiology, and follow-up for longer 
periods of time to determine NDI outcomes, using standardized 
timing of neurodevelopmental assessment with tools validated 
in the context. To investigate the long-term impact of infant 
infection, particularly in terms of NDI, longer-term cohort 
studies are required (Figure 5). To avoid recruitment bias, study 
participants should be well described, including data on, for 
example, comorbidities, and gestational age and birthweight, 
which (if low) can contribute to NDI. Furthermore, while we 
have focused on physical NDI, a comprehensive assessment of 
all child development outcomes, including socioemotional and 
behavioral outcomes, would also improve understanding of the 
total burden of NDI after infant GBS disease [55, 56].
CONCLUSIONS
GBS is a leading cause of infant meningitis, and almost 
one-fifth of GBS meningitis survivors experience moderate 
or severe NDI. There is an additional, as yet unquantified 
burden associated with other invasive infant disease, such 
as GBS sepsis. It is critical to look toward improving the 
health and well-being of survivors of infant GBS disease, 
and supporting their families, for whom there are financial, 
social, psychological, and emotional impacts. Prevention 
strategies (intrapartum antibiotic chemoprophylaxis) for 
Figure 5. “Iceberg” of data available on neurodevelopmental outcomes after infant group B streptococcal (GBS) disease.
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early-onset invasive infant GBS disease are currently lim-
ited to developed countries, and only around the time of 
birth. Maternal GBS vaccination may be able to reduce the 
burden of GBS disease further, particularly GBS menin-
gitis, which mainly presents as late-onset disease beyond 
7 days of life (Table 3).
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